Quantcast

Latest Ewing's sarcoma Stories

2012-07-02 10:24:09

Ewing´s sarcoma is a bone cancer commonly diagnosed in about 250 U.S. teenagers per year. If early chemotherapy is effective, improvement can be durable. But for children and teens who respond poorly to a first attempt at chemotherapy or if the disease spreads, long-term survival can be less than 10 percent. A University of Colorado Cancer Center study published this week in the journal Molecular Cancer Research shows an important difference that may explain why some respond and some...

2011-05-27 16:00:00

INDIANAPOLIS, May 27, 2011 /PRNewswire/ -- In the press release, "Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas," issued May 19, 2011, by Eli Lilly and Company (NYSE: LLY), the following sentence has been amended to: The best overall responses were as follows: one partial response in the Ewing sarcoma tier (n=1); and no partial responses, but stable disease of 41 percent (n=9) in leiomyosarcoma; 35 percent (n=6) in synovial sarcoma; 28 percent (n=5) in Ewing family of...

2011-05-19 07:10:00

INDIANAPOLIS, May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body. Study results demonstrated that 57 percent of patients with a soft tissue sarcoma known as adipocytic sarcoma (a rare tumor that develops from fat cells) experienced stable disease. Results from the Phase II study will be presented on Monday, June 6 at 4:15 p.m. CDT...

2011-05-02 12:26:53

A drug developed to treat Ewing's Sarcoma, a rare childhood cancer, may also help prevent human prostate cancer from spreading, as seen in new lab studies say researchers at Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center (GUMC). Published online April 29 in PLoS ONE, the researchers report that if the agent continues to work well in further laboratory and preclinical studies, it may be the first prostate cancer drug specifically designed to...

2010-12-23 02:11:54

Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia. Now, a team of researchers, led by Aykut Ãœren, at Georgetown University Medical Center, Washington, has generated data using human cancer cell lines that suggest that ATO might also be of benefit to individuals with certain brain tumors or...

2010-09-01 14:37:03

RNAi screening used for the first time to study Ewing's sarcoma The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute (TGen) published this month in the journal Molecular Cancer. Ewing's sarcomas are rare, but aggressive cancer lesions that occur most frequently in the bones of teenagers. They represent nearly...

2010-04-29 12:52:00

NEW YORK, April 29 /PRNewswire-USNewswire/ -- The Sarcoma Foundation of America (SFA)'s Eighth Annual Fundraising Gala on Monday, April 26, raised more than $925,000, an all-time record for the non-profit group dedicated to increasing research that will find new and better therapies for patients with sarcoma, a rare connective tissue cancer. Funding from the Gala directly supports grants for sarcoma researchers and assists with education and advocacy initiatives on behalf of sarcoma...

2010-02-09 07:53:47

Ewing sarcoma (EWS) is a bone tumor of unknown cellular origin that affects children and young adults. The protein CD99 is highly expressed in most cases of EWS, but its function in the disease is unknown. Now, Katia Scotlandi and colleagues, at SSN Emilia Romagna Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy, have identified a crucial role for CD99 in the development of EWS and suggest that targeting CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS. In...

2009-11-06 08:00:00

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.